SARS News and Research

RSS

Southeast Asia - A hotspot of many viruses with potential to cause pandemics

A new study reveals that scientists have found three viruses in bats in Laos that exhibit similar characteristic features as SARS-CoV-2.

28 Sep 2021

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A new study discusses the development of dedicated reagents against the SARS-CoV-2 spike protein through the use of an automated CLEIA system.

28 Sep 2021

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

One recent study provided nationwide estimates of the burden of SARS-CoV-2 that could be averted by Israel's vaccination campaign.

28 Sep 2021

Seven symptoms can be used to maximize detection of COVID-19

A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.

28 Sep 2021

The role of heating, ventilation, and air-conditioning in virus transmission, including SARS-CoV-2

A new study provides an overview of reviews to identify previous systematic reviews on HVAC systems and airborne transmission of infectious agents.

28 Sep 2021

The effectiveness of mRNA BNT162b2 vaccine in reducing severe COVID-19: Evidence from Germany

A new study discusses the epidemiology of the outbreak in German nursing homes and the preventive measures undertaken.

28 Sep 2021

New findings highlight the need to expand the toolbox to fight against COVID-19

When Kamlendra Singh flew back to Missouri from India in April, he developed a cough and fever on the plane, despite being vaccinated for COVID-19 and testing negative for the virus right before departure.

28 Sep 2021

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants.

28 Sep 2021

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

Hamilton Company and Rhinostics are combining their respective strengths to improve the speed and quality of nasal and nasopharyngeal sample workflows.

From Hamilton Process Analytics 28 Sep 2021

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

In a study conducted at the European Institute of Oncology, scientists have found that the risk and duration of SARS-CoV-2 infection reduced significantly after COVID-19 vaccination.

28 Sep 2021

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

New findings identify CASP4/11 as detrimental to inflammation and coagulopathy associated with SARS-CoV-2 infection.

28 Sep 2021

Scientists create new compliance-based model for SARS-CoV-2 transmission

Researchers from Utrecht University have been investigating the interactions between compliance social distance measurements, infection, and vaccination coverage in order to inform public health policy further. A research paper covering their work is available on the medRxiv* preprint server.

28 Sep 2021

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Researchers from the University of Oxford and the University of Warwick have collaborated to develop a method to better understand and evaluate these pleiomorphisms.

28 Sep 2021

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

It has been demonstrated in recent studies that there is a significant breadth of emerging autoreactivity associated with severe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. More specifically, researchers from Emory University have identified a relaxation of peripheral tolerance within early antibody secretion cells that arise in individuals infected with SARS-CoV-2, as important drivers of those responses.

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Risk factors associated with in-school transmission of SARS-CoV-2

As schools resume in the United States and COVID-19 cases amongst children begin to rise, a new study published on the medRxiv* preprint server has highlighted the risk factors for in-school transmission of COVID-19. They also provide evidential support for the layered prevention strategies in schools settings.

28 Sep 2021

COVID Moonshot receives key funding to accelerate drug discovery efforts

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from Wellcome, on behalf of the Covid-19 Therapeutics Accelerator.

28 Sep 2021

Confinement drastically reduced the transmission of COVID-19 variants in Spain during first wave

The most complete studies on the variants of the coronavirus that dominated the first waves in Spain have just been published in Nature Genetics. The study was carried out by the SeqCOVID consortium, which includes more than 50 Spanish institutions led by the University of Valencia, the Institute of Biomedicine of Valencia (IBV, CSIC), and the Fisabio Foundation.

28 Sep 2021

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

A team of scientists from China and the USA has recently described the antiviral efficacy of a monoclonal antibody candidate targeting the spike receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Importantly, they have observed that emerging spike mutations could not affect the potency of this antibody. The study is currently available on the bioRxiv* preprint server.

27 Sep 2021

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Researchers in Japan have conducted a study showing that the vaccine developed by Pfizer-BioNTech to protect against coronavirus disease 2019 (COVID-19) seems to be adequately effective against the B.1.621 (mu) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

27 Sep 2021

SARS News and Research

Southeast Asia - A hotspot of many viruses with potential to cause pandemics

Quantification of antibody titers against SARS-CoV-2 variants elicited by BNT162b2 vaccine

A retrospective surveillance study of Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccination in Israel

Seven symptoms can be used to maximize detection of COVID-19

The role of heating, ventilation, and air-conditioning in virus transmission, including SARS-CoV-2

The effectiveness of mRNA BNT162b2 vaccine in reducing severe COVID-19: Evidence from Germany

New findings highlight the need to expand the toolbox to fight against COVID-19

NIAID awards approximately $36.3 million to fuel vaccine research for coronaviruses

Hamilton and Rhinostics Reinvent Rapid Swab-Based Sample Workflows from Collection to Processing

COVID-19 vaccination reduces risk and duration of SARS-CoV-2 infection

Caspase-11 identified as regulator of inflammatory pathology in SARS-CoV-2 infections

Scientists create new compliance-based model for SARS-CoV-2 transmission

Super-resolution imaging and size analysis of SARS-CoV-2 virus particles

Evidence of persisting autoreactivity in post-acute sequelae of SARS-CoV-2 infection?

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Risk factors associated with in-school transmission of SARS-CoV-2

COVID Moonshot receives key funding to accelerate drug discovery efforts

Confinement drastically reduced the transmission of COVID-19 variants in Spain during first wave

Scientists identify potential antibody candidate with broad-spectrum neutralizing efficacy against SARS-CoV-2 variants

Pfizer-BioNTech’s COVID-19 vaccine appears effective against SARS-CoV-2 mu variant

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News